Frespaciguat
Overview of the drug Frespaciguat
| Frespaciguat | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Frespaciguat is a pharmaceutical compound that acts as a soluble guanylate cyclase (sGC) stimulator. It is being investigated for its potential therapeutic effects in treating various cardiovascular conditions, particularly those involving pulmonary hypertension.
Mechanism of Action[edit | edit source]
Frespaciguat functions by directly stimulating soluble guanylate cyclase, an enzyme that plays a crucial role in the nitric oxide signaling pathway. This pathway is important for the regulation of vascular tone, blood pressure, and cardiac function. By enhancing the activity of sGC, Frespaciguat increases the levels of cyclic guanosine monophosphate (cGMP), leading to vasodilation and improved blood flow.
Therapeutic Applications[edit | edit source]
Frespaciguat is primarily being studied for its use in treating pulmonary arterial hypertension (PAH), a condition characterized by high blood pressure in the arteries of the lungs. This condition can lead to right heart failure and is associated with significant morbidity and mortality. By promoting vasodilation in the pulmonary vasculature, Frespaciguat may help reduce the pressure in these arteries and improve symptoms in patients with PAH.
Clinical Development[edit | edit source]
The development of Frespaciguat involves several phases of clinical trials to assess its safety, efficacy, and optimal dosing. Early-phase trials focus on determining the pharmacokinetics and pharmacodynamics of the drug, while later phases evaluate its therapeutic benefits and potential side effects in larger patient populations.
Side Effects[edit | edit source]
As with many medications, Frespaciguat may cause side effects. Commonly reported adverse effects include headache, dizziness, and nausea. More serious side effects could involve significant drops in blood pressure, leading to symptoms such as syncope or hypotension.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
